Dry eye disease (DED) is a highly prevalent syndrome that manifests with symptoms that include constant irritation, burning or stinging sensations, and feelings of grittiness in the eyes. “DED is a chronic pain syndrome often...
Read MorePrevious research has shown that patients undergoing hematopoietic stem cell transplantation (HSCT) for hematologic malignancies, such as leukemia and lymphoma, are at a high risk of developing graft-versus-host disease (GVHD)....
Read MoreDry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability. The disease can significantly decrease quality of life as it impacts an...
Read More
Acute side-effects of radiation therapy (RT) are often underrecognized by the physicians of...
Read More
An online tool (RSClin) incorporating clinical-pathologic data and results of the 21-gene...
Read More
Meeting Brief… A subgroup of patients participating in the randomized phase III NALA study...
Read More
The omission of radiotherapy (RT) does not affect overall survival at 10 years after breast...
Read More
Pregnancy is less likely after prior breast cancer (BC) diagnosis, according to a systematic...
Read More
MONDAY, Dec. 14, 2020 (HealthDay News) — Pregnancy is less likely after prior breast cancer...
Read More
Addition of selinexor to bortezomib and dexamethasone reduces neuropathy The triple combination of...
Read More
Projection shows increases by lines of therapy Physicians treating multiple myeloma can expect to...
Read MoreHBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Read MoreContributing to this article, Shahzad I. Mian, MD, Professor, Ophthalmology and Visual Sciences, Vice Chair, Clinical Sciences and Learning, Kellogg Eye Center, Michigan Medicine Previous research has shown that patients...
Read MoreReaching RAPID3 and cDAPSA Treatment Targets Linked with Active PsA Control in DMARD-naïve Patients Treated with Apremilast Disease-modifying anti-rheumatic drug (DMARD)-naïve patients achieving Routine Assessment of Patient...
Read MoreResults from Phase 2 PoS Trial In patients with active psoriatic arthritis (PsA) , deucravacitinib was efficacious versus placebo (PBO) over 16 weeks of treatment. Treatment was well tolerated and the safety profile was...
Read More
New research was presented at FMX 2020, the 2020 American Academy of Family Physicians virtual...
Read MoreThe results of CONTESSA, a Phase 3 study of tesetaxel in the treatment of patients with metastatic breast cancer, have been selected for an oral presentation at the 2020 SABCS, to be held virtually December 8-11, 2020. The...
Read MoreHomologous recombination deficiency represents a new therapeutic strategy for breast cancer brain metastases Nicola S Cosgrove BACKGROUND: Brain metastatic disease occurs in 10-30% of metastatic breast cancer cases. The...
Read MoreThe collaborative Phase 3 PENELOPE-B will be presented at SABCS 2020. No unexpected safety signals were observed. Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in...
Read MoreNew Data for HER2 and HER3 Directed DXd ADCs at SABCS includes longer follow-up research data for ENHERTU® based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark...
Read More
